Forging strategic partnerships can help us realize the full potential of our science and enable us to share knowledge, resources and ideas that may best benefit patients. We are committed to alliances, partnerships and collaborations with major universities and other companies that help us bring additional discovery platforms and therapeutics forward. We also evaluate assets that have the potential to expand our pipeline, geographic reach or technological base. We value working with like-minded partners who share our mission to improve the lives of patients.
Additionally, we provide our investigational products and/or financial support for independent research by third parties in therapeutic areas of interest. We ensure that requests for Investigator-Initiated Research (IIRs) are submitted, reviewed and, if approved, conducted and funded in a standardized and consistent manner, in compliance with all applicable legal and ethical standards and obligations.
SOME OF OUR CURRENT COLLABORATIONS
Antibody development collaboration
Discovery collaboration for oncology targeted protein degraders
Multi-product dermatology development and commercialization in Asia
Oncology commercialization collaboration in Asia
Commercialization collaboration in Asia
JAK inhibitor anti-inflammatory diseases and COVID-19 collaboration
Monoclonal antibody development collaboration
Topical JAK inhibitor development and commercialization collaboration in Japan
Bispecific antibody development collaboration
Oncology, hematology and graft-versus-host disease collaboration
Monoclonal antibody development and commercialization collaboration